سعر اكسيلون 4.5 مجم 28 كبسولة 2024

Rivastigmine 4.5 mg oral hard capsules (Exelon, Novartis), pack of 28.

• Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Population: AdultsEuropean Medicines Agency
• Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.Population: AdultsEuropean Medicines Agency

• Most common adverse reactions are gastrointestinal, including nausea (38%) and vomiting (23%), especially during titration; female patients are more susceptible to GI reactions and weight loss.International label, same product · European Medicines Agency

• Hypersensitivity to rivastigmine, to other carbamate derivatives or to any of the excipients; previous history of application site reactions suggestive of allergic contact dermatitis with rivastigmine patch.International label, same product · European Medicines Agency

• Gastrointestinal disorders such as nausea, vomiting and diarrhoea are dose-related and may occur when initiating treatment and/or increasing the dose, more commonly in women; dehydration from prolonged vomiting or diarrhoea can have serious outcomes and should be managed with IV fluids and dose reduction or discontinuation.International label, same product · European Medicines Agency
• Patients with Alzheimer's disease may lose weight on cholinesterase inhibitors; monitor weight during therapy.International label, same product · European Medicines Agency
• QT prolongation and bradycardia (a risk factor for torsade de pointes) may occur; caution in patients with pre-existing or family history of QTc prolongation, uncompensated heart failure, recent myocardial infarction, bradyarrhythmias, hypokalaemia or hypomagnesaemia predisposition, or QT-prolonging medicines; ECG monitoring may be required.International label, same product · European Medicines Agency

• Succinylcholine-type muscle relaxantsRivastigmine may exaggerate their effects during anaesthesia; caution in selecting anaesthetic agents; dose adjustment or temporary interruption may be considered.European Medicines Agency
• Other cholinomimetic substancesShould not be given concomitantly because of possible additive effects.European Medicines Agency
• Anticholinergic medicines (e.g. oxybutynin, tolterodine)Rivastigmine might interfere with their activity.European Medicines Agency

• In animals rivastigmine and/or metabolites crossed the placenta; no clinical data on exposed pregnancies; should not be used during pregnancy unless clearly necessary.International label, same product · European Medicines Agency
• Rivastigmine is excreted in animal milk and it is not known whether it is excreted in human milk; women on rivastigmine should not breast-feed.International label, same product · European Medicines Agency

English text not available for this section.